Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Henan Lingrui Pharmaceutical Co Ltd
Income from Continuing Operations
Henan Lingrui Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
|
Income from Continuing Operations
¥802.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥5.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Income from Continuing Operations
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
244%
|
CAGR 10-Years
N/A
|
|
Henan Lingrui Pharmaceutical Co Ltd
Glance View
Nestled in the heart of China's Henan province, Henan Lingrui Pharmaceutical Co Ltd has quietly crafted a legacy in the pharmaceutical sector, blending traditional Chinese medicine with modern medical practices. Founded in an environment rich in natural resources, the company takes pride in its extensive portfolio that includes a broad range of pharmaceutical products such as tablets, injections, ointments, and Chinese patent medicines. The company's approach is an intricate dance between ancient wisdom and contemporary science, where herbal remedies are often synthesized with cutting-edge pharmaceutical manufacturing processes. Priding itself on research and development, Lingrui regularly collaborates with esteemed medical institutions, ensuring that its offerings remain both innovative and deeply rooted in traditional therapeutic principles. The financial heartbeat of Henan Lingrui is sustained through a strategic balance of domestic sales and international exports, capitalizing on the rising global demand for natural and alternative medicines. As the company expands its footprint, it continues to harness its robust supply chain and distribution channels to seamlessly deliver its products to hospitals, pharmacies, and health institutions across various regions. Indeed, the harmonious blend of traditional and modern methodologies not only defines Lingrui's operations but also shapes its revenue streams. By adhering to stringent quality standards and fostering partnerships, Henan Lingrui Pharmaceutical not only thrives in its local market but also competes in diverse international arenas, leveraging its unique product offerings as a cornerstone for financial growth.
See Also
What is Henan Lingrui Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
802.2m
CNY
Based on the financial report for Sep 30, 2025, Henan Lingrui Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 802.2m CNY.
What is Henan Lingrui Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
21%
Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Henan Lingrui Pharmaceutical Co Ltd have been 22% over the past three years , 22% over the past five years , and 21% over the past ten years .